AlphAIalphai — Financial news for AI agents
aol.comAUG 223 min read$ANNX

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

Original reporting
aol.com
Published Aug 22, 2026, 2:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 5:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Annexon (ANNX) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$ANNXNeutralMed
01

Why it matters

The Q2 earnings and trial updates provide fresh data for valuation and pipeline risk assessment.

02

Market read

Earnings and trial progress are primary catalysts for Annexon's stock movement.

03

What to watch

The new $200M credit facility provides runway, reducing near-term financing risk.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Annexon is a clinical-stage biotech focusing on complement inhibition for rare diseases.

Company-level read

Ticker impact

$ANNXNeutralHigh confidence
Context

Annexon reported Q2 2026 financial results, including a net loss of $55.3M and a $200M credit facility, plus clinical updates on ARCHER II and GBS programs.

Expected impact

Potential short-term volatility as investors digest higher losses versus long runway and clinical progress; upside if trial data remains positive.

Evidence & confidence

Financials are material for valuation; clinical updates are material for biotech catalysts.

Market effects

Sector

Biotech sector may see increased interest in complement inhibition therapies.

Regional

U.S. biotech investors may adjust exposure to early-stage ophthalmology and neurology assets.

Global

Clinical data could influence global partners and competitors in GBS and geographic atrophy treatments.

Counterpoint

What could challenge this read

Higher cash burn and net loss may outweigh trial enrollment gains, suggesting caution.

Key entities

  • Executive
    Douglas Love

    President and CEO of Annexon

  • Clinical Trial
    ARCHER II

    Phase III geographic atrophy trial with expanded enrollment

Read at source← All news

Related articles

AUG 19
$ANNXMedAI 8/10

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.

fool.com3 min
AUG 12
$ANNXMed

Annexon Q2 Earnings Call Highlights

Annexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.

yahoo.com5 min
AUG 12
$ANNXMed

Annexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon

Annexon Biosciences (ANNX) reported Q2 2026 results and clinical updates. It said Phase 3 FORWARD tanruprubart in Guillain-Barre has treated the first 10 U.S. and European patients and expects a Q4 2026 BLA filing. For vonaprument in geographic atrophy, ARCHER II remains on track with Month 15 data in Q4 2026 and final completion in Q3 2027. Q2 R&D was $46.6M, net loss $55.3M. Cash was $209.2M. A $200M credit facility was arranged with $50M drawn.

rttnews.com6 min
AUG 12
$SMCIHighAI 8/10

Super Micro jumps premarket on outlook boost, H&R Block surges

U.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.

investing.com4 min
AUG 12
$ANNXMedAI 8/10

Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.

finanznachrichten.de7 min
AUG 12
$ANNXMed

Annexon Biosciences: Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label

Annexon, Inc. (Nasdaq: ANNX) said it added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument for geographic atrophy in dry AMD, alongside the existing Month 15 endpoint. It also launched an open-label extension for long-term safety and benefit. Month 15 DMC assessment is expected in Q4 2026, with Month 24 results in Q3 2027.

finanznachrichten.de3 min